MedTrace Logo

Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder

NCT05554094 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-03-04

No results posted yet for this study

Summary

The primary aim of this study is to assess the safety and efficacy of psilocybin-assisted therapy in the treatment of post-traumatic stress disorder in United States military Veterans.

Conditions

  • PTSD
  • Stress Disorders, Traumatic
  • Stress Disorders, Post-Traumatic
  • Trauma and Stressor Related Disorders
  • Mental Disorder

Interventions

DRUG

Psilocybin

Participants will receive 15 mg of oral psilocybin in the first session and 25 mg in the second session.

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Principal Investigators

  • Alan K Davis, PhD · Ohio State University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2025-12-31
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05554094 on ClinicalTrials.gov